Alpharadin, a 223Ra-based α-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer

Current Opinion in Investigational Drugs

Volumn 10, Issue 12, 2009, Pages 1346-1358

  Liepe, Knut ^a  

^a Hospital Kassel   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ALPHARADIN RA 223; HEMOGLOBIN; PAMIDRONIC ACID; PLACEBO; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; RADIUM;

ADVANCED CANCER; ALPHA RADIATION; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MORBIDITY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PERIPHERAL EDEMA; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; ANIMAL; BONE TUMOR; DISEASE COURSE; METASTASIS; NEOPLASM; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SURVIVAL RATE;

ALPHA PARTICLES; ANIMALS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; NEOPLASMS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RADIUM; SURVIVAL RATE;

EID: 71249088083     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (187)

1. 20619 Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG EUR J NUCL MED 1989 15 12 784-795
2. 82349 Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate. Lowik CW, van der Pluij M, van der Weepals LJ, van de Groot HB, Bijvoet OL J BONE MINER RES 1988 3 2 185-192
3. 121725 Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Yagoda A, Petrylak D CANCER 1993 71 3 1098-1109 (Pubitemid 23049638)
4. 122654 Palliative pamidronate treatment in patients with bone metastases from breast cancer. Van Holten Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, Vermey P et al J CLIN ONCOL 1993 11 3 491-498
5. 127926 Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo. Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ et al J NUCL MED 1991 32 10 1877-1881
6. 167928 Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR J NUCL MED 1993 34 11 1839-1844
7. 194388 Samarium-153-EDTMP in bone metastases. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J, Larikka M et al J NUCL BIOL MED 1994 38 4 Suppl 1 123-127
8. 194395 Targeted radionuclide therapy for bone metastases. Lewington VJ EUR J NUCL MED 1993 20 1 66-74
9. 194421 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Ketring AR NUCL MED BIOL 1987 14 3 223-232
10. 196204 Docetaxel. Cortes JE, Pazdur R J CLIN ONCOL 1995 13 10 2643-2655
11. 216620 Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies. Maxon HR, Deutsch EA, Thomas SR, Libson K, Lukes SJ, Williams CC, Ali S RADIOLOGY 1988 166 2 501-507
12. 278014 Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. Conte PF, Latreille J, Mauriac L, Calabresi R, Santos R, Campos D, Bonneterre J, Francini G, Ford JM J CLIN ONCOL 1996 14 9 2552-2559
13. 359250 Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P CANCER RES 1997 57 18 3890-3894
14. 377783 Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P CANCER RES 2000 60 11 2949-2954
15. 392099 Cellular and molecular mechanisms of action of bisphosphonates. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC CANCER 2000 88 12 Suppl 2961-2978
16. 425483 Stimulation of bone-resorption and inhibition of bone-formation in vitro by human-tumor necrosis factors. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR NATURE 1986 319 6053 516-518
17. 482380 The pharmacology of bisphosphonates and new insights into their mechanisms of action. Russell RGG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA J BONE MINER RES 1999 14 Suppl 2 53-65
18. 493198 Phase I clinical trial exploring the bone-seeking ? emitter radium-223 in patients with skeletal metastases from breast and prostate cancer. Nilsson S, Balteskard L, Fossa SD, Westlin JE, Borch KW, Traasdahl E, Salberg G, Larsen RH, Bruland OS PROC AM SOC CLIN ONCOL, 2003 22 Abs 963
19. 503127 State-of-the-art treatment of metastatic hormonerefractory prostate cancer. Goodin S, Rao KV, DiPaola RS ONCOLOGIST 2002 7 4 360-370
20. 537259 Bisphosphonates induce breast cancer cell death in vitro. Fromigue O, Lagneaux L, Body JJ J BONE MINER RES 2000 15 11 2211-2221
21. 760592 Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, AlSharif A, Chioni A, Di Donato S et al EUR J NUCL MED MOL IMAGING 2007 34 7 1023-1030
22. 813805 Oral sodium clodronate for nonmetastatic prostate cancer - Results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, Stott M, Robinson AC, James ND, Parmar MK, Dearnaley DP J NATL CANCER INST 2007 99 10 765-776
23. 853313 A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DR, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB CANCER 2007 110 9 1959-1966
24. 878640 Algeta receives IND approval for Alpharadin to commence clinical development in the USA. Algeta ASA PRESS RELEASE 2008 February 21
25. 896293 Cellular effects of ? particle radiation from radium-223: Alpharadin, a new radiopharmaceutical for the treatment of skeletal metastases. Dornish M, Heier-Baardson H, Pettersen EO AM ASSOC CANCER RES ANN MEET 2008 99 April 16 Abs 5749
26. 916972 A biodistribution and dosimetry study of therapeutic 223Ra-chloride (Alpharadin) in patients with osteoblastic skeletal metastases secondary to hormone refractory prostate cancer. Hindorf C, Flux GD, Lewington V, Aksnes AK, Harris P, Parker C ABS SOC NUCLEAR MED ANN MEET 2008 55th June 18th Abs 576
27. 934422 Algeta begins first US clinical trial of Alpharadin in men with advanced prostate cancer. Algeta ASA PRESS RELEASE 2008 August 12
28. 945461 Metastasis to bone: Causes, consequences and therapeutic opportunities. Mundy GR NAT REV CANCER 2002 2 8 584-593
29. 976057 First clinical experience with ?-emitting radium-223 in the treatment of skeletal metastases. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS CLIN CANCER RES 2005 11 12 4451-4459 Pain palliation was observed in the majority of patients, and BAP levels were decreased by 52.1 and 29.5% from baseline in the prostate and breast cancer groups, respectively. Accumulation of the drug was observed in the bone metastases. Hematological DLTs were not observed.
30. 976058 Targeting of osseous sites with ?-emitting 223Ra: Comparison with the ?-emitter 89Sr in mice. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH J NUCL MED 2003 44 2 252-259
31. 976059 223Ra for endoradiotherapeutic applications prepared from an immobilized 227Ac/227Th source. Henriksen G, Alstad J, Hoff P, Larsen RH RADIOCHIMICA ACTA 2001 89 10 661-666
32. 976065 Significant antitumor effect from bone-seeking, ?-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH CANCER RES 2002 62 11 3120-3125 Bone marrow retention was low compared with bone matrix retention.
33. 976069 Phase I study of Alpharadin (223Ra), an ?-emitting bone-seeking agent in cancer patients with skeletal metastases. Nilsson S, Balteskard L, Fossa SD, Westlin JE, Bruland OS, Larsen RH, Borch KW EUR J NUCL MED MOL IMAGING 2004 31 Suppl 2 Abs 370
34. 976072 Bone-seeking radium-223 adjuvant to external beam radiotherapy demonstrates significant decline in bone-alkaline phosphatase and PSA in patients with hormone refractory prostate cancer (HRPC). Nilsson S, Franzen L, Tyrrell C, Blom R, Tennvall J, Lennernas B, Yachnin J, Johannessen DC, Sokal M, Bruland OS ASCO PROSTATE CANCER SYMP 2006 Abs 215
35. 976073 A randomized, placebo-controlled, phase 2 study of radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Twelve months follow-up data. Nilsson S, Franzen L, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Johannessen DC, Sokal M, Parker C, Bruland OS ASCO PROSTATE CANCER SYMP 2007 Abs 259
36. 976075 Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Results from a randomized, placebo-controlled, phase II study. Nilsson S, Franzen L, Tyrrell C, Blom R, Tennvall J, Lennernas B, Johannessen DC, Sokal M, Parker C, Bruland OS J CLIN ONCOL 2007 25 18 Suppl Abs 5071
37. 976085 Bone-targeted radium-223 in symptomatic, hormonerefractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K et al LANCET ONCOL 2007 8 7 587-594
38. 976086 Radiotoxicity of the ?-emitting bone-seeker 223Ra injected intravenously into mice: Histology, clinical chemistry and hematology. Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottir TJ, Bruland OS, Klastrup S, Harling R, Ramdahl T IN VIVO 2006 20 3 325-331
39. 976410 Algeta completes comprehensive phase II clinical program with Alpharadin for treating bone metastases in patients with advanced prostate cancer. Algeta ASA PRESS RELEASE 2009 January 14
40. 978474 Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC). Nilsson S, Franzen L, Tyrrell C, Blom R, Tennvall J, Lennernas B, Johannessen DC, Sokal M, Parker C, Bruland OS EUR J CANCER 2007 5 4 Abs 4054
41. 978475 Tolerability of a novel bone-seeking radionuclide - the ? emitter radium-223 - in patients with skeletal metastases from breast and prostate cancer. Nilsson S, Balteskard L, Fossa SD, Westlin J-E, Borch K, Larsen RH, Bruland OS EUR J CANCER 2003 1 5 Abs 543
42. 1015816 Clinical development of bone-seeking 223Ra (Alpharadin): Current status. Bruland O ABS SOC NUCLEAR MED ANN MEET 2009 June 14 Abs 35
43. 1039121 Algeta signs $800 million (€560m) global agreement with Bayer for development and commercialization of Alpharadin for bone metastases. Algeta ASA PRESS RELEASE 2009 September 03
44. 1039259 Bayer and Algeta enter global agreement for development and commercialization of treatment for bone metastases in cancer patients. Bayer Schering Pharma AG PRESS RELEASE 2009 September 03
45. 1044010 New phase II data presented at ECCO 15 - 34th ESMO Congress reinforces exciting potential of Algeta's Alpharadin as a new treatment for bone metastases in cancer patients. Algeta ASA PRESS RELEASE 2009 September 22
46. 1050612 The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogencontaining bisphosphonates. van beek E, Lowik C, van der Pluijm G, Papapoulos S J BONE MINER RES 1999 14 5 722-729
47. 1051182 A double-blind, randomised dose-response phase II, multicentre study of radium-223 for the palliation of painful bone metastases in castration refractory prostate cancer patients. Nilsson S, Strang P, Franzen L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland OS, Aksnes AK EJC SUPPL 2009 7 2 Abs P-7011
48. 1051184 ?-Emitting radium-223: Two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer. Nilsson S, Franzen L, Parker C, Bolstad B, Ramdahl T, Thuresson M, Bruland O EJC SUPPL 2009 7 2 Abs P-7018
49. 1051186 A double blind, randomised, dose finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005-003680-3722 Parker C, Hoskin P, Pascoe S, Chodack A, O'Sullivan JM, Germa JR, Lokna A EJC SUPPL 2009 7 2 Abs O-7003
50. 1053621 Palliative therapy with bone seeking radiopharmaceuticals. McEwan AJB CANCER BIOTHER RADIOPHARM 1998 13 6 413-426
51. 1053631 The role of androgens and the androgen receptor in prostate cancer. Debes JD, Tindall DJ CANCER LETT 2002 187 1-2 1-7
52. 1053632 Chemotherapy for prostate cancer. Gilligan T, Kantoff PW UROLOGY 2002 60 3A 94-100
53. 1053634 Metastatic bone disease: Clinical and therapeutic aspects. BODY JJ BONE 1992 13 S57-S62
54. 1053635 Skeletal metastases. Galasko CS CLIN ORTHOP 1986 210 18-30
55. 1053636 Chemotherapy of metastatic cancer in bone. Bhardwaj S, Holland JF CLIN ORTHOP 1982 169 28-37
56. 1053637 Molecular mechanisms of cancer pain. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP NAT REV CANCER 2002 2 3 201-209
57. 1053638 Bone metastases: Pathophysiology and management policy. Nielsen OS, Munro AJ, Tannock IF J CLIN ONCOL 1991 9 3 509-524
58. 1053640 Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate ancer cells in vivo. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D INT J CANCER 1999 80 2 257-264
59. 1053641 Bone destruction in cancer. Ross Garrett I SEMIN ONCOL 1993 20 3 Suppl 2 4-9
60. 1053642 Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Zhang Y, Fujita N, Oh-hara T, Morinaga Y, Nakagawa T, Yamada M, Tsuruo T ONCOGENE 1998 16 6 693-703
61. 1053646 Bone metastases: Pathogenesis, treatment, and rationale for use of resorption inhibitors. Scher HI, Yagoda A AM J MED 1987 82 2A 6-28
62. 1053649 Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS CANCER METASTASIS REV 2001 20 3-4 333-349
63. 1053652 Adhesion, chemotaxis, and aggregation of walker carcinosarcoma cells in response to products of resorbing bone. Magro C, Orr FW, Manishen WJ, Sivananthan K, Mokashi SS J NATL CANCER INST 1985 74 4 829-838
64. 1053654 The cellular basis of metastatic bone-disease in patients with lung-cancer. Cramer SF, Fried L, Carter KJ CANCER 1981 48-12 2649-2660
65. 1053659 Association of increased cyclic adenosine 3'-5'-monophosphate content in cultured human-breast cancer-cells and release of hydrolytic enzymes and bone-resorbing activity. Eilon G, Mundy GR CANCER RES 1983 43 12 5792-5794
66. 1053664 Relation of osteoclast activating factor production to extent of bone-disease in multiple-myeloma. Durie BG, Salmon SE, Mundy GR BR J HAEMATOL 1981 47 1 21-30
67. 1053666 Stimulation of bone-resorption in vitro by synthetic transforming growth factor-?. Ibbotson KJ, Twardzik DR, D'Souza SM, Hargreaves WR, Todaro GJ, Mundy GR SCIENCE 1985 228 4702 1007-1009
68. 1053669 Carcinoma of the breast associated with hyper-calcemia and the presence of parathyroid hormone-like substances in the tumor. Hirshorn JE, Vrhovsek E, Posen S J CLIN ENDOCRINOL METAB 1979 48 2 217-221
69. 1053671 Effect of growth-factors on bone cell replication and differentiation. Canalis E CLIN ORTHOP 1985 193 246-263
70. 1053676 Correlation between bone metabolic markers and bone scan in prostatic cancer. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E J UROL 1997 157 2 539-543
71. 1053677 Biochemical markers and skeletal metastases. Demers LM, Costa L, Lipton A CANCER 2000 88 12 2919-2926
72. 1053679 Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Coleman RE CANCER TREAT REV 2001 27 3 165-176
73. 1053682 Biology of osteoclast activation in cancer. Roodman GD J CLIN ONCOL 2001 19 15 3562-3571
74. 1053684 Spinal cord compression from epidural metastases. Byrne TN N ENGL J MED 1992 327 9 614-619
75. 1053685 Bone metastases - The clinical problem. Rubens RD EUR J CANCER 1998 34 2 210-213
76. 1053686 Cancer pain relief and palliative care. Report of a WHO expert committee. World Health Organization WHO TECH REP SER 1990 804 1-75
77. 1053687 Cancer pain: Pathophysiology and syndromes. Portenoy RK LANCET 1992 339 8800 1026-1031
78. 1053692 Management of cancer of the prostate. Catalona WJ N ENGL J MED 1994 331 15 996-1004
79. 1053701 Management of advanced prostate cancer. Auclerc G, Antoine EC, Cajfinger F, Brunet-Pommeyrol A, Agazia C, Khayat D ONCOLOGIST 2000 5 1 36-44
80. 1053704 Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S et al J CLIN ONCOL 1997 15 9 3156-3163
81. 1053707 Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/ prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W J CLIN ONCOL 2003 21 17 3335-3342
82. 1053720 Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K, Lehnert M, Stettner H, Hubmer G EUR UROL 1997 32 Suppl 3 81-85
83. 1053727 Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Petrioll R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G UROLOGY 2007 69 1 142-146
84. 1053728 The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G CANCER TREAT REV 2008 34 8 710-718
85. 1053745 Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN ONCOLOGIST 2001 6 2 133-146
86. 1053756 Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM CANCER 1979 44 5 1955-1962
87. 1053761 Paclitaxel versus doxorubicin as first-line singleagent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. Paridaens R, Biganzoli L, Bruning P, Klijn JGM, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A et al J CLIN ONCOL 2000 18 4 724-733
88. 1053774 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC J CLIN ONCOL 2003 21 4 588-592
89. 1053787 Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy. Valero V SEMIN ONCOL 1997 24 4 S11-S18
90. 1053790 Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A minnie pearl cancer research network phase II trial. Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA J CLIN ONCOL 2001 19 15 3500-3505
91. 1053979 Phase II study of weekly docetaxel in patients with metastatic breast cancer. Aihara T, Kim Y, Takatsuka Y ANN ONCOL 2002 13 2 286-292
92. 1053983 Bisphosphonates and breast carcinoma. Lipton A CANCER 1997 80 8 1668-1673
93. 1053987 Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI BR J HAEMATOL 1997 98 3 665-672
94. 1054005 The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI BR J CANCER 2001 84 8 1126-1134
95. 1054007 Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Rizzoli R, Forni M, Schaad MA, Slosman DO, Sappino AP, Garcia J, Bonjour JP BONE 1996 18 6 531-537
96. 1054011 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M et al N ENGL J MED 1996 335 24 1785-1791
97. 1054013 Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD et al J CLIN ONCOL 1999 17 3 846-854
98. 1054021 Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Van Beek ER, Lowik CWGM, Papapoulos SE BONE 2002 30 1 64-70
99. 1054022 Reduction in new metastases in breast cancer with adjuvant clodronate treatment. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G N ENGL J MED 1998 339 6 357-363
100. 1054024 Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M et al J CLIN ONCOL 2002 20 15 3219-3224
101. 1054026 Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. Saarto T, Blomqvist C, Virkkunen P, Elomaa I J CLIN ONCOL 2001 19 1 10-17
102. 1054049 Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Heidenreich A, Elert A, Hofmann R PROSTATE CANCER PROSTATIC DIS 2002 5 3 231-235
103. 1054051 Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F ANN ONCOL 2006 17 6 986-989 (Pubitemid 43778991)
104. 1054109 The role of radiotherapy in management of metastatic bone disease. Kumar PP, Bahrassa F, Espinoza MC J NATL MED ASSOC 1978 70 12 909-911
105. 1054110 Effectiveness of radiation-therapy in treatment of bone metastases from breast-cancer. Garmatis CJ, Chu FC RADIOLOGY 1978 126 1 235-237
106. 1054112 Radiation-therapy for bone metastasis. Schocker JD, Brady LW CLIN ORTHOP 1982 169 38-43
107. 1054117 The palliation of symptomatic osseous metastases: Final results of the study by the Radiation Therapy Oncology Group. Tong D, Gillick L, Hendrickson FR CANCER 1982 50 5 893-899
108. 1054124 The responsiveness of bone metastases to radiotherapy: The effect of site, histology and radiation dose on pain relief. Arcangeli G, Micheli A, Arcangeli G, Giannarelli D, Lapasta O, Tollis A, Vitullo A, Ghera S, Benassi M RADIOTHER ONCOL 1989 14 2 95-101
109. 1054132 The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the Dutch Bone Metastasis Study. Steenland E, Leer J, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, de Haes H, Martijn H, Oei B, Vonk E, van der Steen-Banasik E et al RADIOTHER ONCOL 1999 52 2 101-109
110. 1054141 Palliative radiotherapy in the treatment of skeletal metastases. Saarto T, Janes R, Tenhunen M, Kouri M EUR J PAIN 2002 6 5 323-330
111. 1054148 Pain relief and quality of life following radiotherapy for bone metastases: A randomised trial of two fractionation schedules. Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A, Howard GCW, Rodger A RADIOTHER ONCOL 1997 45 2 109-116
112. 1054149 Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR RADIOTHER ONCOL 1998 47 3 233-240
113. 1054150 Single-dose radiotherapy (6 Gy): Palliation in painful bone metastases. Uppelschoten JM, Wanders SL, de Jong JM RADIOTHER ONCOL 1995 36 3 198-202
114. 1054151 Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Blitzer PH CANCER 1985 55 7 1468-1472
115. 1054157 Radiation therapy in the management of symptomatic bone metastases: The effect of total dose and histology on pain relief and response duration. Arcangeli G, Giovinazzo G, Saracino B, D'Angelo L, Giannarelli D, Arcangeli G, Micheli A INT J RADIAT ONCOL BIOL PHYS 1998 42 5 1119-1126
116. 1054160 Bone metastasis: Review and critical analysis of random allocation trials of local field treatment. Ratanatharathorn V, Powers WE, Moss WT, Perez CA INT J RADIAT ONCOL BIOL PHYS 1999 44 1 1-18
117. 1054162 Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate. Kuban DA, Delbridge T, el-Mahdi AM, Schellhammer PF J UROL 1989 141 3 572-574
118. 1054164 Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Salazar OM, Rubin P, Hendrickson FR, Komaki R, Poulter C, Newall J, Asbell SO, Mohiuddin M, Vaness J CANCER 1986 58 1 29-36
119. 1054172 A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NSE, Russell JM, Yardley J RADIOTHER ONCOL 1994 31 1 33-40
120. 1054174 Impending pathologic fractures from metastatic malignancy: Evaluation and management. Harrington KD INSTR COURSE LECT 1986 35 357-381
121. 1054180 Metastatic bone disease: Current concepts of clinicopathophysiology and modern surgical treatment. Sim FH, Frassica FJ, Frassica DA ANN ACAD MED SINGAPORE 1992 21 2 274-279
122. 1054181 Fracture-healing in metastatic bone-disease. Gainor BJ, Buchert P CLIN ORTHOP 1983 178 297-302
123. 1054182 Role of postoperative radiation-therapy after stabilization of fractures caused by metastatic disease. Townsend PW, Smalley SR, Cozad SC, Rosenthal HG, Hassanein RE INT J RADIAT ONCOL BIOL PHYS 1995 31 1 43-49
124. 1054183 Cavity theory applied to the dosimetry of systemic radiotherapy of bone metastases. Breen SL, Battista JJ PHYS MED BIOL 2000 45 4 879-896
125. 1054186 The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Friedell HL, Storaasli JP AM J ROENTGENOL 1950 64 4 559-575
126. 1054189 The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Silberstein EB SEMIN ONCOL 1993 20 3 10-21
127. 1054191 Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. Nair N J NUCL MED 1999 40 2 256-261
128. 1054198 Palliative radiotherapy with strontium-89 in case of extended formation of skeleton metastases. Kutzner J, Grimm W, Hahn K STRAHLENTHERAPIE 1978 154 5 317-322
129. 1054202 Strontium-89 therapy for the pain of osseous metastases. Silberstein EB, Williams C J NUCL MED 1985 26 4 345-348
130. 1054204 Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Robinson RG, Blake GM, Preston DF, McEwan AJ, Spicer JA, Martin NL, Wegst AV, Ackery DM RADIOGRAPHICS 1989 9 2 271-281
131. 1054206 Strontium-89 therapy: Strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma. Blake GM, Zivanovic MA, McEwan AJ, Condon BR, Ackery DM BR J RADIOL 1987 60 711 253-259
132. 1054213 A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA EUR J CANCER 1991 27 8 954-958
133. 1054215 Systemic radionuclide therapy of bone metastases with strontium-89. Porter AT, Davis LP ONCOLOGY-NY 1994 8 2 93-96
134. 1054216 Strontium-89 therapy for the palliation of pain due to osseous metastases. Robinson RG, Preston DF, Schiefelbein M, Baxter KG JAMA-J AM MED ASSOC 1995 274 5 420-424
135. 1054218 Yttrium-90 treatment of bone metastases. Kutzner J, Grimm W, Brod KH, Roesler A DTSCH MED WOCHENSCHR 1982 107 36 1360-1361
136. 1054220 Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: A pilot study. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, D'Alessandro T J NUCL MED 1995 36 5 725-729
137. 1054221 Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF, Biersack HJ EUR J NUCL MED 2000 27 2 123-130
138. 1054222 Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Liepe K, Kropp J, Runge R, Kotzerke J BR J CANCER 2003 89 4 625-629 (Pubitemid 37076163)
139. 1054230 99mTc(V)DMSA quantitatively predicts 188Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Blower PJ, Kettle AG, O'Doherty MJ, Coakley AJ, Knapp FF EUR J NUCL MED 2000 27 9 1405-1409
140. 1054231 A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA J CLIN ONCOL 1989 7 12 1926-1931
141. 1054234 Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A J NUCL MED 1992 33 8 1451-1458
142. 1054235 Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Sandeman TF, Budd RS, Martin JJ CLIN ONCOL-UK 1992 4 3 160-164
143. 1054241 A dose-controlled study of 153Sm-ethylenediaminetetr amethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D EUR J CANCER 1997 33 10 1583-1591
144. 1054242 Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ EUR J NUCL MED 1999 26 1 2-7
145. 1054243 Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Serafini AN CANCER 2000 88 12 2934-2939
146. 1054246 Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect. Li L, Liang ZL, Deng HF, Kuang AR, Tan TZ, Luo SZ CHIN MED J (ENGL) 2002 115 7 1096-1098
147. 1054247 Absorbed dose calculations in Haversian canals for several ?-emitting radionuclides. Akabani G J NUCL MED 1993 34 8 1361-1366
148. 1054254 Alkaline earth metabolism in adult man. Marshall JH, Lloyd EL, Rundo J, Liniecki J, Marotti G, Mays CW, Sissons HA, Snyder WS HEALTH PHYS 1973 24 2 125-221
149. 1054256 Mean skeletal dose factors for ?-particle emitters in human bone. Part I: Volume-seeking radionuclides. Spiers FW, Beddoe AH, Whitwell JR BR J RADIOL 1978 51 608 622-627
150. 1054260 Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Hosain F, Spencer RP SEMIN NUCL MED 1992 22 1 11-16
151. 1054261 Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. Breen SL, Powe JE, Porter AT J NUCL MED 1992 33 7 1316-1323
152. 1054265 Phosphate homeostasis and hypophosphatemia. Stoff JS AM J MED 1982 72 3 489-495
153. 1054267 Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. de Klerk JM, Zonnenberg BA, van het Schip ADV, Vandijk A, Han SH, Quirijnen JMSP, Blijham GH, Vanrijk PP EUR J NUCL MED 1994 21 10 1114-1120
154. 1054269 Overview of nuclides for bone pain palliation. Atkins HL APPL RADIAT ISOT 1998 49 4 277-283
155. 1054271 A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. Turner JH, Claringbold PG, Hetherington EF, Sorby PF, Martindale AA J CLIN ONCOL 1989 7 12 1926-1931
156. 1054272 Rhenium-188(Sn)HEDP for treatment of osseous metastases. Maxon HR, Schroder LE, Washburn LC, Thomas SR, Samaratunga RC, Biniakiewicz D, Moulton JS, Cummings D, Ehrhardt GJ, Morris V J NUCL MED 1998 39 4 659-663
157. 1054273 Rhenium-188-HEDP in the palliative treatment of bone metastases. Liepe K, Hliscs R, Kropp J, Gruning T, Runge R, Koch R, Knapp FF, Franke WG CANCER BIOTHER RADIOPHARM 2000 15 3 261-265
158. 1054274 Rhenium-188 HEDP to treat painful bone metastases. Li SJ, Liu JZ, Zhang H, Tian M, Wang J, Zheng XO CLIN NUCL MED 2001 26 11 919-922
159. 1054277 Repeated bone-targeted therapy for hormonerefractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IGH, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S et al J CLIN ONCOL 2003 21 15 2869-2875
160. 1054278 Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: A phase I/II clinical study. Srivastava SC, Atkins HL, Krishnamurthy GT, Zanzi I, Silberstein EB, Meinken G, Mausner LF, Swailem F, D'Alessandro T, Cabahug CJ, Lau Y et al CLIN CANCER RES 1998 4 1 61-68
161. 1054280 Use of radium-224 in the treatment of ankylosing spondylitis and rheumatoid synovitis. Bertrand A, Legras B, Martin J HEALTH PHYS 1978 35 1 57-60
162. 1054282 Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. Wick RR, Nekolla EA, Gaubitz M, Schulte TL RHEUMATOLOGY 2008 47 6 855-859
163. 1054283 Bone-targeted therapy for advanced androgenindependent carcinoma of the prostate: A randomised phase II trial. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA et al LANCET 2001 357 9253 336-341
164. 1054284 Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL J NUCL MED 2002 43 1 79-86
165. 1054286 Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E et al J CLIN ONCOL 2009 27 15 2429-2435
166. 1054289 Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Soerdjbalie-Maikoe V, Pelger RCM, Nijeholt GABL, Arndt JW, Zwinderman AH, Papapoulos SE, Hamdy NAT EUR J NUCL MED MOL IMAGING 2002 29 4 494-498
167. 1054290 Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled trial. Porter AT, McEwan AJ SEMIN ONCOL 1993 20 3 38-43
168. 1054291 Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: Results of a double-blind randomized study. Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD INT J RADIAT ONCOL BIOL PHYS 2003 56 5 1397-1404
169. 1054292 Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G et al CLIN CANCER RES 2003 9 7 2587-2597
170. 1054294 Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Honore P, Luger NM, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW NAT MED 2000 6 5 521-528
171. 1054295 Transforming growth factor-? stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA J BIOL CHEM 2002 277 27 24571-24578
172. 1054296 Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, Fukumoto S, Matsumoto T ENDOCRINOLOGY 1995 136 3 1276-1284
173. 1054299 Epidermal growth factor receptor modulation of radiation response: Preclinical and clinical development. Harari PM, Huang SM SEMIN RADIAT ONCOL 2002 12 3 21-26
174. 1054302 Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva). Chinnaiyan P, Huang S, Armstrong E, Harari PM INT J RADIAT ONCOL BIOL PHYS 2003 57 2 Suppl S294
175. 1054965 Breast disease. Haris JR, Hellmann S, Henderson IC CHEMOTHERAPY METASTATIC DIS (ED: HENDERSON I) 1991 Lippincott Company, Philadelphia, PA, USA 2nd Edition 604-655
176. 1054979 Single-dose irradiation of bone metastases. Jensen NH, Roesdahl K ACTA RADIOLOGICA: THERAPY, PHYSICS, BIOL 1976 15 4 337-339
177. 1055004 Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Pecher P UNIV CALIFORNIA PUBLICATIONS PHARMACOL 1942 2 117-149
178. 1055033 Comparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metastatic bone pain: Results of an IAEA coordinated research Project. Fettich J, Padhy A, Nair N, Morales R,Tamumihardja M, Riccabonna G, Nair G WORLD J NUCLEAR MED 2003 2 226-231
179. 1055045 Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. Enrique O, Zhonyun P, Prma EP, Pusuwan P, Ricobona G, Tian JH, Obaldo J, Padhy AK WORLD J NUCLEAR MED 2002 1 21-27
180. 1055052 Iodine-131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. Eisenhut M, Berberich R, Kimmig B, Oberhausen E J NUCL MED 1986 27 8 1255-1261 (Pubitemid 17030120)
181. 1055065 Treatment of bone metastases of prostate cancer with strontium-89 chloride: Efficacy in relation to the degree of bone involvement. Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I EUR J NUCL MED 2000 27 10 1487-1493
182. 1055067 A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A EUR J NUCL MED 2001 28 7 788-798 (Pubitemid 32662540)
183. 1055068 Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, Zivanovic MA BR J RADIOL 1991 64 765 816-822
184. 1055070 Bone pain palliation with 85Sr therapy. Giammarile F, Mognetti T, Blondet C, Desuzinges C, Chauvot P J NUCL MED 1999 40 4 585-590
185. 1055309 Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G J UROL 1976 115 1 86-88
186. 1055894 Atomic weights of the elements. Review 2000 (IUPAC Technical Report). de Laeter JR, Böhlke JK, de Bièvre P, Hidaka H, Peiser HS, Rosman KJR, Taylor PDP PURE APPL CHEM 2003 75 6 683-800
187. 1056922 Drug development update: Alpharadin. COMPANY COMMUNICATION Algeta ASA 2009 November 06